Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous version (v2.14.2) and date of March 4, 2025.SummaryDifference0.1%
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has updated its date references, removing older dates and adding new ones for March 2025.SummaryDifference0.2%
- Check29 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check38 days agoChange DetectedThe webpage has updated its date references, removing older dates and adding new ones for February 2025.SummaryDifference0.2%
- Check45 days agoChange DetectedThe page now includes a notice about heavy traffic affecting NLM-NCBI services and updates the dates for upcoming events, removing two previous dates.SummaryDifference0.9%
- Check52 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.